EUVIMEDEUVIMED entdecken
Historischer BeitragOpen Access · CC BY-NC-ND 4.0

Discovery and development of a bispecific antibody for the treatment of hemophilia

William Pao iD

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2622459123 ↗

Kurz gefasst

Historischer Beitrag in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von William Pao. Beteiligte Einrichtung: Revelio Therapeutics Inc, New York, NY 10016. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Factor VIII, Hemophilia A. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2026 Lasker~DeBakey Clinical Medical Research Award has been awarded to Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa (Chugai Pharmaceuticals, Tokyo, Japan) for invention of a bispecific antibody that joins blood clotting Factors IXa (FIXa) and X (FX), restoring deficient Factor VIII (FVIII) activity in patients with hemophilia A and preventing severe bleeding in this hereditary disorder. Starting from the 1960s, types of FVIII-replacement therapy remarkably improved on-demand hemostatic treatment for ongoing bleeds and enabled prophylactic reduction of bleeding episodes. However, these agents required burdensome intravenous infusions multiple times per week, and ~30% of patients developed neutralizing anti-FVIII antibodies (FVIII inhibitors). To address these unmet medical needs, in 2000, Hattori—a molecular and hematology biologist, Kitazawa—a hematology biologist and translational researcher, and Igawa—a biochemist and protein engineer, conceived, designed, and created over the span of 10 y a novel FVIII-mimetic. Instead of a native protein construct, they engineered a bispecific IgG antibody against FIXa and FX, circumventing the need for FVIII and enabling subcutaneous administration up to once per month. Importantly, they identified the biophysical requirements for the bispecific to mimic FVIII function effectively and safely, and their breakthrough protein engineering design made possible favorable pharmacokinetics and physicochemical properties with efficient manufacturability. Their collective research efforts demonstrate how imagination, determination, and multidisciplinary scientific research come together to improve patients’ lives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificFactor VIIIHemophilia AAnimalsHumansFactor IXaFactor XHistory, 19th CenturyHistory, 20th CenturyHistory, 21st CenturyAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ACE910Factor VIII-mimeticbispecific antibodyemicizumabhemophilia A

Substanzen

Antibodies, BispecificemicizumabFactor IXaFactor VIIIFactor XAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Revelio Therapeutics Inc, New York, NY 10016.

ORCID-Profile: William Pao

Zitieren

APA

Pao, W. (2026). Discovery and development of a bispecific antibody for the treatment of hemophilia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2622459123

Vancouver

Pao W. Discovery and development of a bispecific antibody for the treatment of hemophilia. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2622459123

BibTeX
@article{Pao2026,
  author = {Pao, William},
  title = {Discovery and development of a bispecific antibody for the treatment of hemophilia},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2622459123}
}
Kostenlos starten →